ATE457307T1 - Synthese von 2-hydroxy-n,n-dimethyl-3-[[2-[1(r)- (5-methyl-2-furanyl)propyl amino -3,4-dioxo-1- cyclobuten-1-yl amino benzamid - Google Patents

Synthese von 2-hydroxy-n,n-dimethyl-3-[[2-[1(r)- (5-methyl-2-furanyl)propyl amino -3,4-dioxo-1- cyclobuten-1-yl amino benzamid

Info

Publication number
ATE457307T1
ATE457307T1 AT04759956T AT04759956T ATE457307T1 AT E457307 T1 ATE457307 T1 AT E457307T1 AT 04759956 T AT04759956 T AT 04759956T AT 04759956 T AT04759956 T AT 04759956T AT E457307 T1 ATE457307 T1 AT E457307T1
Authority
AT
Austria
Prior art keywords
amino
cyclobuten
dioxo
furanyl
hydroxy
Prior art date
Application number
AT04759956T
Other languages
English (en)
Inventor
Jianguo Yin
Xiaoyong Fu
Shuyi Zhang
Timothy Mcallister
Agnes Kim-Meade
Jason Winters
Anantha Sudhakar
Doris Schumacher
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ATE457307T1 publication Critical patent/ATE457307T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/58Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/60Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Furan Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT04759956T 2003-04-18 2004-04-16 Synthese von 2-hydroxy-n,n-dimethyl-3-[[2-[1(r)- (5-methyl-2-furanyl)propyl amino -3,4-dioxo-1- cyclobuten-1-yl amino benzamid ATE457307T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46377303P 2003-04-18 2003-04-18
PCT/US2004/011882 WO2004094398A2 (en) 2003-04-18 2004-04-16 Synthesis of 2-hydroxy-n,n-dimethyl-3-[[2-[1(r)-(5-methyl-2-furanyl)propyl]amino]-3,4-dioxo-1-cyclobuten-1-yl]amino]benzamide

Publications (1)

Publication Number Publication Date
ATE457307T1 true ATE457307T1 (de) 2010-02-15

Family

ID=33310818

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04759956T ATE457307T1 (de) 2003-04-18 2004-04-16 Synthese von 2-hydroxy-n,n-dimethyl-3-[[2-[1(r)- (5-methyl-2-furanyl)propyl amino -3,4-dioxo-1- cyclobuten-1-yl amino benzamid

Country Status (13)

Country Link
US (3) US7071342B2 (de)
EP (2) EP1615903B1 (de)
JP (2) JP4440917B2 (de)
CN (3) CN101514168B (de)
AR (1) AR044027A1 (de)
AT (1) ATE457307T1 (de)
CA (1) CA2522748C (de)
DE (1) DE602004025458D1 (de)
ES (1) ES2338657T3 (de)
MX (1) MXPA05011183A (de)
SG (1) SG167671A1 (de)
WO (1) WO2004094398A2 (de)
ZA (3) ZA200508129B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040106794A1 (en) * 2001-04-16 2004-06-03 Schering Corporation 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
KR100883476B1 (ko) * 2004-01-30 2009-02-16 쉐링 코포레이션 Cxc-케모킨 수용체 리간드의 결정성 다형체
AU2007258325B2 (en) 2006-06-12 2013-02-21 Merck Sharp & Dohme Corp. Pharmaceutical formulations and compositions of a selective antagonist of either CXCR2 or both CXCR1 and CXCR2 and methods of using the same for treating inflammatory disorders
WO2009005801A1 (en) * 2007-07-03 2009-01-08 Schering Corporation Process and intermediates for the synthesis of 1,2-substituted 3,4-dioxo-1-cyclobutene compounds
CN101778836A (zh) * 2007-07-05 2010-07-14 先灵公司 在1,2-取代的3,4-二氧-1-环丁烯化合物中控制的晶体大小的方法
EP2583960A4 (de) * 2010-06-16 2015-07-15 Teijin Ltd Verfahren zur herstellung von zwischenprodukten für eine zyklische carbodiimidverbindung
WO2012147897A1 (ja) * 2011-04-25 2012-11-01 住友化学株式会社 アミン化合物の製造方法
TWI724056B (zh) 2015-11-19 2021-04-11 美商卡默森屈有限公司 Cxcr2抑制劑
TWI734715B (zh) 2015-11-19 2021-08-01 美商卡默森屈有限公司 趨化因子受體調節劑
US11052065B2 (en) 2017-09-27 2021-07-06 Merck Sharp & Dohme Corp. Compositions and methods for treating cancer with a combination of programmed death receptor (PD-1) antibodies and a CXCR2 antagonist
MA50424A (fr) 2018-01-08 2020-08-26 Chemocentryx Inc Méthodes de traitement du psoriasis pustuleux généralisé avec un antagoniste de ccr6 ou cxcr2
TWI849253B (zh) * 2019-11-11 2024-07-21 美商富曼西公司 用於製備3-溴-1- (3-氯吡啶-2-基) -1h-吡唑-5-羧酸乙酯的方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2791613A (en) * 1953-08-24 1957-05-07 Columbia Southern Chem Corp Metahaloaniline production using copper oxide-chromic oxide catalysts
CH691112A5 (de) 1995-03-14 2001-04-30 Sumitomo Chemical Co Verfahren zur Herstellung von Kristallen eines Schwefelsäuresalzes des 3-Amino-2-hydroxyacetophenons mit hoher Schüttdiche und verbesserten Fliesseigenschaften .
ZA991105B (en) * 1998-03-04 2000-02-11 Searle & Co Synthesis of chiral beta-amino acids.
US20030204085A1 (en) * 2001-02-02 2003-10-30 Taveras Arthur G. 3, 4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor antagonists
PL367534A1 (en) * 2001-02-02 2005-02-21 Schering Corporation 3,4-di-substituted cyclobutene-1, 2-diones as cxc chemokine receptor antagonists
ES2287284T3 (es) * 2001-04-16 2007-12-16 Schering Corporation Ciclobuteno-1,2-dionas disustituidas en las posiciones 3,4 como ligandos de receptores de quimiocinas cxc.
US20040106794A1 (en) 2001-04-16 2004-06-03 Schering Corporation 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
US20040053953A1 (en) 2002-03-18 2004-03-18 Schering Corporation Treatment of chemokine mediated diseases
US12284102B2 (en) 2022-09-01 2025-04-22 Dell Products, L.P. Detection of collaboration sessions and other workloads in a heterogenous computing platform

Also Published As

Publication number Publication date
CN100448860C (zh) 2009-01-07
EP1615903B1 (de) 2010-02-10
JP2006523616A (ja) 2006-10-19
ZA200800486B (en) 2009-07-29
CA2522748A1 (en) 2004-11-04
EP2168956B8 (de) 2013-05-01
JP4440917B2 (ja) 2010-03-24
ZA200800487B (en) 2009-08-26
CN101514168B (zh) 2014-02-26
US7462740B2 (en) 2008-12-09
WO2004094398A3 (en) 2005-03-03
JP2010053139A (ja) 2010-03-11
CN101514193A (zh) 2009-08-26
US7910775B2 (en) 2011-03-22
JP5202503B2 (ja) 2013-06-05
CN1805947A (zh) 2006-07-19
US20060205961A1 (en) 2006-09-14
DE602004025458D1 (de) 2010-03-25
MXPA05011183A (es) 2005-12-14
CN101514193B (zh) 2012-12-19
SG167671A1 (en) 2011-01-28
CN101514168A (zh) 2009-08-26
HK1078315A1 (en) 2006-03-10
US20040209946A1 (en) 2004-10-21
EP2168956B1 (de) 2013-03-20
AR044027A1 (es) 2005-08-24
EP2168956A3 (de) 2010-07-14
EP2168956A2 (de) 2010-03-31
US20090048458A1 (en) 2009-02-19
CA2522748C (en) 2011-06-28
EP1615903A2 (de) 2006-01-18
ES2338657T3 (es) 2010-05-11
WO2004094398A2 (en) 2004-11-04
ZA200508129B (en) 2008-04-30
US7071342B2 (en) 2006-07-04

Similar Documents

Publication Publication Date Title
ATE261930T1 (de) Asymmetrische synthese von pregabalin
ATE457307T1 (de) Synthese von 2-hydroxy-n,n-dimethyl-3-[[2-[1(r)- (5-methyl-2-furanyl)propyl amino -3,4-dioxo-1- cyclobuten-1-yl amino benzamid
BRPI0415710A (pt) formas polimórficas de n-[(r)-2,3-dihidróxi-propóxi]-3,4-diflúor-2-(2-flúor-4-io dofenilamino)-benzamida
ATE337090T1 (de) Synthese von molekularsiebkatalysatoren
EP1634645A4 (de) Katalysator für die acrylnitril-synthese
ATE530516T1 (de) Exo- und diastereoselektive synthese von himbacin-analoga
ATE353878T1 (de) Pyridyloxyalkancarbonsäureamid-derivate verwendbar als fungizide
ATE349436T1 (de) Lipidsenkende biphenylcarbonsäureamide
FR2829139B1 (fr) Synthese d'elastomeres trans-1,4-polybutadiene, a haute teneur en motifs trans
ATE381263T1 (de) Fungizide zusammensetzungen, die n-(alpha-cyano-2-thenyl)-4-ethyl-2-ethylamino-5 thiazolcarboxamide enthalten
WO1999055687A3 (en) Hydroxypropylamide peptidomimetics as inhibitors of aspartyl proteases
HRP20040920A2 (en) Novel form of n-(trans-4-isopropylcyclohexylcarbonyl)-d-phenylalanine
BG105143A (en) Fluorophenyl resin comopunds
IS2707B (is) Nýjar lyfjasamsetningar úr módafíníli
DE69901024D1 (de) Asymmetrischen synthese von 2-aryl-1-substituierten butan-2,3-diolen
ITMI20020991A0 (it) Procedimento per la sintesi del modafinil
EP1809616A4 (de) Synthese von aminosäure-n-carboxyanhydriden
DE69820435T2 (de) Gelbe polymorphe Form von 5-Amino-2,4,6-triiodo-N,N'-bis (2,3-dihydroxypropyl)isophthalamid
ATE327987T1 (de) Methylthiophencarboxanilide
EP1534783A4 (de) Synthese von cis-diolen aus arylsilanen
DE50205590D1 (de) Ummantelung von leiterbahnen
DK1644340T3 (da) N-[ ( { ' 4-substitueret piperazin-1-yl } sulfonylmethyl ) alkyl ] -N-hydroxyformamidforbindelser som metalloproteinaseinhibitorer
BR0317956A (pt) sìntese de (r) e (s)-aminocarnitina e derivados das mesmas a partir de ácido d e l-aspártico
EP1391198A4 (de) Neuer sphingolipid-synthese-hemmer
IL175742A0 (en) Insecticidal n-(heteroarylalkyl) alkanediamine derivatives

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties